menu
    • menu
    [{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Preclinical","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Superluminal Medicines \/ RA Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Superluminal Medicines

    Menu

    Superluminal Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Superluminal Medicines

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Superluminal Medicines Closes $120 Million Series A Round

                            Details : The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value GPCR targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Superluminal Medicines

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : RA Capital Management

                            Deal Size : $33.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of ...

                            Details : The funding will be used to progress Superluminal’s pipeline of small molecule drug discovery programs initially focused on high-value G protein-coupled receptor (GPCR) targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : RA Capital Management

                            Deal Size : $33.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth